sampleAnti-inflammatory · oral
99%+ · 0.5mg · Tablets · MW: 342.43
Bulk discount
3+ pcs
€71.25
−5%
5+ pcs
€67.50
−10%
10+ pcs
€63.75
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
KPV Tablets 500 mcg × 30
α-MSH Tripeptide (Lys-Pro-Val) | Oral Anti-Inflammatory Research | IBD Focus
In short
Tripeptide fragment of α-MSH studied for anti-inflammatory activity via inhibition of the NF-κB pathway in tissue models.
Best sellers
Related resources
KPV is an extremely small peptide, consisting of just three amino acids, derived from the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH). At the molecular level, it enters cells and modulates specific signaling pathways, reducing the cellular production of key inflammatory markers. Researchers are actively studying it in in vitro and animal models due to its stable structure, which resists degradation in the digestive tract and allows for oral experimental formulations. This product is strictly for laboratory research purposes and is not an approved medication or therapeutic treatment for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
KPV is the smallest known α-MSH-derived peptide that retains anti-inflammatory activity. The three-residue sequence (Lys-Pro-Val) corresponds to the C-terminus of α-MSH and engages melanocortin signaling along with MC1R-independent intracellular pathways. Its compact structure resists proteolytic degradation in the gut lumen — a property exploited in oral research formulations targeting intestinal inflammation.
Exceptional GI stability — oral viability Inhibits NF-κB activation Reduces TNF-α, IL-6 in inflamed tissue models Smallest peptide retaining α-MSH anti-inflammatory activity
KPV downregulates NF-κB activation in inflamed enterocytes and macrophages, reducing TNF-α, IL-6, and IL-1β output. The peptide also enters cells through PEPT1 transporter and modulates intracellular signaling independent of cell-surface MC1R, broadening its anti-inflammatory reach.
Oral KPV reduced colitis severity in DSS-induced mouse models with comparable efficacy to higher-dose α-MSH (Kannengiesser et al, Inflamm Bowel Dis 2008).
Adverse events in published research are minimal. The peptide is small, well-tolerated, and lacks signaling promiscuity at typical research doses. Pigmentation effects (a known α-MSH class signal at higher MC1R activation) have not been reported with KPV at research doses.
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
KPV reduces experimental colitis
Mouse | Inflamm Bowel Dis 2008
Kannengiesser et al. showed that oral KPV reduced DSS-induced colitis in mice with comparable efficacy to higher-dose α-MSH.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
